Xenon Pharmaceuticals XENE Return on invested capital

Return on invested capital at other companies

Eli LillyLLY

39.7%+10.3pp

Johnson & JohnsonJNJ

19.2%+1.3pp

Jazz PharmaceuticalsJAZZ

-6.1%-14.2pp

Axsome TherapeuticsAXSM

-3,891.6%—

Stoke Therapeutics, Inc.STOK

-114.4%—

Praxis Precision Medicines, Inc.PRAX

-67.9%-17.5pp

FAQ

What is Xenon Pharmaceuticals's return on invested capital?

Xenon Pharmaceuticals (XENE) reported return on invested capital of -54% in Q2 2026.

How has Xenon Pharmaceuticals's return on invested capital changed year-over-year?

Xenon Pharmaceuticals's return on invested capital decreased by 3.9% year-over-year, from -52% to -54%.

What is the long-term trend for Xenon Pharmaceuticals's return on invested capital?

Over 5 years (2020 to 2025), Xenon Pharmaceuticals's return on invested capital has grown at a 20.2% compound annual growth rate (CAGR), from -29.3% to -73.7%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.